HARTFORD, Conn., April 16, 2024 /PRNewswire/ -- Thelansis
Knowledge Partners, specialized in pharmaceutical and
biopharmaceutical business research and consulting
Company that provides data driven research and consulting
support released highly valued Market Outlook Report Title:
Asthma - Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report 2023 To 2033
Asthma is a chronic inflammatory respiratory disease, which
affects adults as well as pediatrics. In the United States, it affects approximately 25
million people, including 5 million children/adolescents. About 1
million asthmatic people in the United
States get hospitalized each year. Globally, asthma impacts
more than 250 million people, reflecting high disease burden. In
addition to the age-group, asthma patients can be categorized into
mild, moderate or severe patients, based on the disease severity
and the treatment required to achieve good asthma control.
Established medications for asthma management include rescue
therapies (e.g., SABA) and maintenance therapies, such as the
fixed-dose combinations (FDCs) of LABA/ICS. The brand share for
LABA/ICS is eroding rapidly in the asthma market because of the
launches of several generics (including authorized generics) in the
recent years in the major markets. Nevertheless, newer therapies,
for example, biologics have been particularly effective for
moderate to severe, uncontrolled asthma patients and have been
gaining inroads for these patients. Spiriva, Nucala, Fasenra,
Cinqair, Dupixent, and Tezspire are the useful treatment options
for refractory asthma, as per interviewed KOLs. Many of these drugs
offer improved patient adherence because of their less-frequent
administration schedules.
Even with the availability of these newer therapies, several
opportunities exist to target niche patient segments in asthma
(e.g., non-TH2 asthma) and to develop more convenient FDC
formulations, among other opportunities. Successfully targeting one
or more of the unmet needs would be a differentiating factor for a
novel emerging drug in asthma, and would enable faster sales and
patient share uptake in the asthma market. Some promising emerging
agents in asthma include,
Emerging
agent
|
Developer
|
Target unmet
need
|
Phase of
development
|
Breztri (a
LABA/LAMA/ICS triple FDC)
|
AstraZeneca
|
Better patient
compliance
|
Phase III
|
Depemokinab (a
longer-acting IL-5 antagonist)
|
GlaxoSmithKline
|
Better patient
compliance
|
Phase III
|
Masitinib (a selective
tyrosine kinase inhibitor)
|
AB Science
|
Targets both
eosinophilic and non-eosinophilic severe asthma
|
Phase III
|
KOL perspectives:
"The emerging triple FDCs will definitely offer more convenience
to patients. However, many patients may not be their candidates
because they don't necessarily need three drugs at a given point of
time to control asthma." - A leading U.S.-based pulmonologist
"The hardest thing would be to offer a cure for asthma. We are
very far from reaching that. I believe we have a good number of
anti-inflammatory drugs, including biologics. Perhaps, we need some
more for specific refractory patients. Now, it's the time to move
the needle for developing drugs toward curing asthma." - A
leading Europe-based
pulmonologist
Key business insights:
Thelansis's Asthma report provides in-depth insights on the
epidemiology and the drug development pipeline for the various
target patient segments in asthma. In addition, the report answers
key questions such as,
- How large is the epidemiology pool for asthma in the 8 major
markets (including U.S., EU5, Japan, and China). How this prevalence will change in the
next ten years (2023-2033)?
- What is the epidemiology of various target patient segments in
asthma?
- What is the market size (in terms of sales) for asthma? What is
the share of various drugs and classes? How will this landscape
evolve in the next ten years?
- What is the treatment algorithm for asthma in the major
markets? How the treatments vary by geography?
- What drugs are preferred in early line and late lines by KOLs?
What are the KOL opinions/quotes on key treatments in asthma?
- What is the competitive landscape in asthma, along with the
commercial potential for key late-phase agents? What are the key
unmet needs in asthma on which drug development can be
focused?
- What is the evolving payer landscape for asthma?
About Thelansis
Thelansis specializes in pharmaceutical and biopharmaceutical
business research and consulting Company, published reports across
the therapeutic area which includes both rare / ultra-rare and
mainstream indications. Over the period, we have built a strong
repository of 6,000+ Bio-pharma reports which essentially cover
Epidemiology studies and Market forecasting, opportunity assessment
based on the KOL Interviews and conference coverage. Competitive
intelligence and conference coverage throughout the phases of asset
development executed by a team of a mix of Scientific and Business
backgrounds. As an organization, the major focus is to provide
real-world data evidence and market insight to pharmaceutical
companies for their decision-making.
Offerings in the respiratory / asthma space: syndicated
reports/offerings for the major
markets, epidemiology, customized market research
including KOL interviews, PMR surveys, pipeline research,
conference coverage, market forecast models, consulting, and payer
insights.
The drug developers can engage Thelansis for customized market
research and can gain on possible solutions for ensuring
considerable market penetration for their respective therapies.
Contact us today on ….
Website: Thelansis.com
Chinmaya Kumar
Senapati
Email- clientsupport@thelansis.com
Contact No.-+91-6397349664
Logo:
https://mma.prnewswire.com/media/2336260/THELANSIS_LOGO.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/asthma---market-outlook-epidemiology-competitive-landscape-and-market-forecast-report-2023-to-2033-302118109.html